ELF3

Across TCGA pan-cancer cohorts, ELF3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELF3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ELF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ELF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where ELF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	1.000	0.643	.004	11	view →
HNSC	DFS	Quartile	III,IV	0.852	1.000	.008	5	view →
PDAC	DFS	Quartile	All	0.834	0.693	.016	4	view →
CCRCC	OS	Quartile	III,IV	1.000	0.619	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELF3–LUAD (OS)

Open the LUAD breakdown →